文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症急性肾损伤合并高循环二肽基肽酶3患者的预后:AKIKI 2试验的事后分析

Prognosis of critically ill patients with severe acute kidney injury and high circulating dipeptidyl peptidase 3: a post hoc analysis of the AKIKI 2 trial.
PubMed 文献 · Crit Care · 2026-03-03
一句话结论在重症急性肾损伤(KDIGO 3期)患者中,诊断时循环二肽基肽酶3(cDPP3)>40 ng/mL与28天死亡率升高及器官支持依赖时间延长相关。

该研究为AKIKI 2试验的事后分析,纳入287例重症急性肾损伤(KDIGO 3期)且接受或曾接受有创机械通气和/或血管加压药支持、入组时有血样的ICU患者,按预设cutoff 40 ng/mL分为cDPP3高浓度组(143例,49.8%)和低浓度组。主要终点28天死亡率:高cDPP3组风险比1.95(95%CI 1.37-2.87,p<0.001)。次要终点无器官支持天数:高cDPP3组无血管加压药天数平均差-5.59(95%CI -8.29至-2.78),无有创机械通气天数平均差-6.23(95%CI -8.89至-3.36),无肾脏替代治疗天数平均差-6.35(95%CI -9.14至-3.26),均p<0.001。校正基线严重度标志物后,上述关联仍显著。

要点

  • 重症急性肾损伤(KDIGO 3期)患者中,cDPP3>40 ng/mL者占49.8%(143/287),28天死亡风险比为1.95(95%CI 1.37-2.87,p<0.001)。
  • cDPP3>40 ng/mL与无血管加压药天数减少5.59天(95%CI -8.29至-2.78)、无有创机械通气天数减少6.23天(95%CI -8.89至-3.36)、无肾脏替代治疗天数减少6.35天(95%CI -9.14至-3.26)相关,均p<0.001。
  • 校正基线严重度标志物后,cDPP3>40 ng/mL与28天死亡率及无器官支持天数的关联仍显著。
  • 该研究为AKIKI 2试验的事后分析,cDPP3为入组时单次检测,预设cutoff 40 ng/mL,尚不能据此推荐常规检测或用于治疗决策。

适用人群与场景

  • ICU中重症急性肾损伤(KDIGO 3期)且正在接受或曾接受有创机械通气和/或血管加压药支持、入组时有血样的患者。

诊断标准与关键阈值

  • 急性肾损伤诊断标准:KDIGO 3期。
  • cDPP3分组阈值:预设cutoff 40 ng/mL,高于此值定义为高cDPP3。

研究设计与关键结果

  • 研究类型:AKIKI 2试验的事后分析;样本量287例;人群为ICU重症急性肾损伤(KDIGO 3期)接受或曾接受有创机械通气和/或血管加压药支持且有血样的患者。
  • 分组:按cDPP3预设cutoff 40 ng/mL分层,高cDPP3组143例(49.8%)。
  • 主要终点:28天死亡率,高cDPP3组风险比1.95(95%CI 1.37-2.87,p<0.001)。
  • 关键次要终点:无血管加压药天数平均差-5.59(95%CI -8.29至-2.78,p<0.001);无有创机械通气天数平均差-6.23(95%CI -8.89至-3.36,p<0.001);无肾脏替代治疗天数平均差-6.35(95%CI -9.14至-3.26,p<0.001)。
  • 校正基线严重度标志物后,cDPP3>40 ng/mL与28天死亡率及无器官支持天数的关联仍显著。

证据类型、等级与局限

  • 证据类型:AKIKI 2试验的事后分析。

对床旁实践的改变

  • 在重症急性肾损伤(KDIGO 3期)接受或曾接受有创机械通气和/或血管加压药支持的患者中,入组时cDPP3>40 ng/mL提示28天死亡风险升高及器官支持依赖时间延长;该指标为预后关联,原文未据此给出治疗推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Acute kidney injury (AKI) is a frequent and severe complication among critically ill patients. Circulating dipeptidyl peptidase 3 (cDPP3), an enzyme released upon cellular injury, has been implicated in hemodynamic instability and organ dysfunction. Its role in severe AKI remains poorly defined. We aimed to assess the prognostic significance of cDPP3 in critically ill patients with severe AKI.

METHODS: In this post hoc analysis of the AKIKI 2 study, we included ICU patients with severe AKI (KDIGO stage 3) who were receiving (or had received) invasive mechanical ventilation and/or vasopressor support and had available blood samples at inclusion. Patients were stratified according to cDPP3 concentration using a predefined cutoff of 40 ng/mL. The primary outcome was 28-day mortality; secondary outcomes were organ support-free days.

RESULTS: Among 287 included patients, 143 (49.8%) had cDPP3 concentrations above 40 ng/mL. High cDPP3 was associated with increased 28-day mortality (hazard ratio 1.95; 95% confidence interval 1.37-2.87, p < 0.001). Furthermore, high cDPP3 was associated with fewer days alive without vasopressors (mean difference - 5.59; 95% CI - 8.29 to - 2.78, p < 0.001), invasive mechanical ventilation (mean difference - 6.23; 95% CI - 8.89 to - 3.36, p < 0.001), or renal replacement therapy (mean difference - 6.35; 95% CI - 9.14 to - 3.26, p < 0.001). After adjustment for baseline markers of severity, both the associations with 28-day mortality and organ support-free days remained significant.

CONCLUSIONS: In critically ill patients with severe AKI, a high cDPP3 concentration at diagnosis is associated with increased short-term mortality and prolonged dependence on organ support.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Picod A, Boussier J, Tubiana S, et al. Prognosis of critically ill patients with severe acute kidney injury and high circulating dipeptidyl peptidase 3: a post hoc analysis of the AKIKI 2 trial. Crit Care. 2026. PMID: 41776654. doi:10.1186/s13054-026-05910-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。